Targeting lung damage in COVID-19 patients with CD34⁺ cell therapy

Doug Losordo is Executive Vice President, Global Head of Research and Development and Chief Medical Officer of Caladrius Biosciences. Dr Losordo’s career has been dedicated to the development of novel therapeutics aimed at the reversal of chronic conditions such as refractory angina, critical limb ischemia, coronary microvascular dysfunction, and heart failure. His guiding principle has been that the restoration of health should be our goal, not the management of ongoing disease. He has developed clinical programs in gene therapy and cell-based tissue repair targeting myocardial ischemia, diabetic neuropathy, refractory angina, critical limb ischemia, severe claudication, coronary microvascular dysfunction and most recently COVID-19 lung damage.

Please enter your email to access content Read now